Home » Corporate Overview »

Directors

Viropro’s Board of Directors is constituted of dynamic individuals and dedicated experts who are the architects of the company's future. Together, they form a top-ranking team of professionals with proven expertise in the pharmaceutical industry, international business development and corporate finance.

 Dr Rajiv Datar

Dr Datar holds a Ph. D in Bioprocess Technology from the Royal Institute of Technology of Stockholm, Sweden and Post-Doctorate in Biochemical Engineering from the Massasuchetts Institute of Technology (MIT). He has graduated as Biochemist / Chemist from the University of Pune, India and has Post-Graduate studies in Chemical Engineering from the University of Manchester, United Kingdom.
 
With 22 years experience in Biotechnology and Bio-Business in Senior Technical positions at major pharmaceutical concerns as well as Senior Management positions for publicly-traded or startup biotech, Dr Datar brings an impressive and extensive expertise to the Company.
 
Moreover, Dr Datar has hands-on knowledge and experience of successful conclusion of business deals, collaborations (across institutions, companies and countries), public issues, in-licensing and out-licensing deals, raising capital, positioning and sale of technologies/departments, takeovers and biotech start-ups. Dr Datar is also member of several Advisory / Boards

Dr Scott M. Brown

Dr. Brown received his Ph.D. in microbiology from UCLA.  After postdoctoral studies in molecular biology at the University of Colorado, Boulder, he began his career in the biotechnology industry. 


Dr. Brown has over 25 years of industrial experience in cloning and expressing heterologous genes in microbial and non-microbial systems as well as protein purification from native and recombinant sources. He has used cell culture systems ranging in size from 5 to 100 L for insect and mammalian cells and up to 1600 L for yeast and bacteria.  Dr. Brown has extensive experience scaling protein purification schemes using FPLC, BioPilot and BioProcess systems with columns up to 45 cm in diameter.

Dr. Brown has acted as liaison and biologics technology transfer supervisor between BPD clients and their contract research and manufacturing organizations.  He has been the recipient of two SBIR grants and is the author of several US and European patents in the broad area of drug development and diagnostic biotechnology. He has also been an invited speaker at both domestic and international meetings.

Since 1996, Dr. Brown has been President and CSO of Biologics Process Development Inc. where he will remain at the helm of the Company.

Emilio Binavince

Mr. Binavince, counsel to the law offices of France Viele, was formerly a partner in Gowling, Strathy & Henderson.  He was educated in the Philippines (LL.B.), United States (M.C.L., Tulane, LL.M., Harvard) and Germany (Doctoral Studies, Bonn).  He is a member of the Bars of Ontario, Saskatchewan and the Philippines.  He was the founding chairman, Joint MBA/LL.B. Program and co-Director of the Graduate Faculty of Law at the University of Ottawa.  He is an advocate of over thirty years and has appeared as counsel in all levels of Court including the Supreme Court of Canada and various administrative tribunals.

Mr. Binavince is active as advisor, corporate director, and legal counsel on business and tax matters of foreign investors and ethnic communities in Canada and of Canadian investors in foreign countries, particularly in the Far East.

He is author of numerous articles and books in his area of practice and interest, and specializes in business and tax planning, and, government litigation.